This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk and Ascendis Pharma have agreed to ... As per the deal signed yesterday (4 November), the two Danish companies will jointly develop therapeutics for metabolic and cardiovascular ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

Novo Nordisk was a pioneer in developing GLP-1 drugs ... The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric ...

The company is due to release data before the end of this year from a late-stage trial of CagriSema, a two-drug combination ... coverage of Danish drugmaker Novo Nordisk and its race to increase ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range. The maker ...

Novo Nordisk remains a sell due to increased competition ... which were labeled as close to patent expiration in the 2023 20-F filing. These two drugs contributed to Novo's sales, but as can ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ... one of the Essence study. Part two is ongoing, with an expected ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

Novo Nordisk (NVO) announced Friday a pivotal Phase ... dose it evaluated indicated a safe and well-tolerated profile. The two-part trial included MASH patients and those with liver fibrosis.